BioSpace News Archive

exoIL-12 demonstrates tumor-retained and dose-dependent pharmacology with superior anti-tumor efficacy compared to soluble recombinant IL-12

Statistically and clinically significant effects on pruritus, xanthomas and growth maintained for up to four years of treatment in Alagille syndrome

First-in-class software platform digitalizes Twist Biopharma’s innovative antibody lead identification and optimization

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data on Vemlidy® (tenofovir alafenamide 25 mg, TAF) that continue to support an improved safety profile compared with tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (HBV) infection.

Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced the company will participate in a fireside chat with analysts and investors at the upcoming 13th Annual Canaccord Genuity Medical Technologies & Diagnostics Forum being held Thursday, November 21, 2019 in New York, NY.

Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today it has been awarded the 2nd phase funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to continue the development of its antibiotic program Debio 1453, leading to a novel FabI inhibitor drug candidate specifically targeting Neisseria gonorrhoeae

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that is has established a new Scientific Advisory Board (SAB)

Cerus Corporation (Nasdaq:CERS) announced today that Kevin D. Green, Cerus’ chief financial officer, will present at the Stephens Nashville Investment Conference on Wednesday, November 13, 2019 at 10:30 a.m. CT.

Four innovative technologies from Dow, the world’s leading materials science company, were recognized with 2019 R&D 100 awards from R&D World magazine and its new parent company, WTWH Media, LLC.

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2019.